CAERO: Genotype Expression and Phenotype of Endothelial Cells, Carrying an ACVRL1, ENG or SMAD4 Mutation, in Response to BMP9 for the Identification of New Therapeutic Targets in Hereditary Haemorrhagic Telangiectasia

• Sponsor: Hospices Civils de Lyon (Other)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT05632484
• Collaborator: (none)
• Enrollment: 16
• Locations: 3
• Arm: 1
• Anticipated Duration (Months): 26.1
• Patients Per Site: 5.3
• Patients Per Site Per Month: 0.2

Study Details

Study Description

Brief Summary

Hereditary hemorrhagic telangiectasia (HHT) or Osler-Weber-Rendu syndrome patients are carriers of a heterozygous mutation of the activin receptor-like kinase 1 (ACVRL1), Endoglin (ENG) or Mothers against decapentaplegic homolog 4 (SMAD4) gene. HHT involves the Bone Morphogenetic Protein 9 (BMP9)/Activin receptor-Like Kinase 1 (ALK1)-endoglin signalling pathway. BMP9 is a growth factor that binds to ALK1 receptor and to endoglin its co-receptors and physiologically activates Smad signaling pathway. Endothelial cells in HHT patients display half expression of functional ALK1 receptors or endoglin co-receptors or of the transcription factor SMAD4, which should lead to effects on the functions of these cells.

The identification of differences in gene expression between endothelial cells from HHT patients and healthy donors will allow the identification of new functions or new target pathways for therapy. Circulating endothelial cells are rare in the bloodstream in adults, but are present in greater quantities in cord blood.

Condition or Disease	Intervention/Treatment	Phase
Hereditary Haemorrhagic Telangiectasia	Biological: Cord blood sampling; Biological: Cord blood sampling; Biological: Cord sampling	N/A

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 16 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Basic Science
• Official Title: Genotype Expression and Phenotype of Endothelial Cells, Carrying an ACVRL1, ENG or SMAD4 Mutation, in Response to BMP9 for the Identification of New Therapeutic Targets in Hereditary Haemorrhagic Telangiectasia
• Anticipated Study Start Date: Dec 1, 2022
• Anticipated Primary Completion Date: Feb 1, 2025
• Anticipated Study Completion Date: Feb 1, 2025

Arms and Interventions

Arm

Intervention/Treatment

Experimental: Newborns with a parent with HHT disease 16 newborns with one parent suffering HHT disease and carrying a mutation in the ACVRL1, ENG or SMAD4 gene will be included in this study.

Biological: Cord blood sampling; Collection of 2 milliliters (mL) of cord blood on an Ethylenediaminetetraacetic acid (EDTA) tube, on the day of delivery and after cutting the umbilical cord, for genetic testing; Biological: Cord blood sampling; Collection of 50 to 100 mL of cord blood from the cord blood collection bag; Biological: Cord sampling; Collection of 20 centimeters (cm) of umbilical cord

Outcome Measures

Primary Outcome Measures

1. Number of Endothelial Colony Forming Cells (ECFC) from cord blood [up to 3 weeks after cells isolation]

   The primary outcome is the obtention of at least one clone of 10 000 cells from the cord blood after 3 weeks from the time of isolation. Number of viable cells is measured by Trypan blue test.

2. Number of Human Umbilical Vein Endothelial Cells(HUVEC) from cord [up to one week]

   For the cord, the primary outcome is the obtention of 500 000 cells after one week from the isolation. Number of viable cells is measured by Trypan blue test.

Secondary Outcome Measures

1. cell freezing and thawing [Through study completion, an average of 5 years.]

   After isolation and amplification, cells from cord or from clones from the cord blood are frozen in vials. The cells viability (50 to 70% of alive cells after thawing) is a criteria of successful experiment.

2. Gene expression quantification after RNA extraction from cells [Through study completion, an average of 5 years.]

   The third outcome is reached when we obtain up to 5 µg of RNA after cell seeding and stimulation with growth factors. Gene expression is measured by real-time polymerase chain reaction (RT-qPCR) and Ribonucleic acid Sequencing (RNAseq).

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Newborn whose parents :

• are adults

• are affiliated to a social security or similar

• are not subject to any legal protection measures

• Newborn child with one parent who has monitored for HHT confirmed by molecular biology (carrier of a mutation of the SMAD4, ENG or ACVRL1 gene).

• Consent signed by the two representatives of parental authority

Exclusion Criteria:

• One of the two parents opposes donating the umbilical cord blood and the umbilical cord for research

• One of the two parents opposes genetic testing

• Patient for whom it was not possible to obtain umbilical cord blood after delivery for technical or medical reasons.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Hôpital Femme-mère-Enfant	Bron		France	69677
2	Hôpital Estaing	Clermont-Ferrand		France	63100
3	Hôpital St Eloi	Montpellier		France	34295

Sponsors and Collaborators

• Hospices Civils de Lyon

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Hospices Civils de Lyon
• ClinicalTrials.gov Identifier: NCT05632484
• Other Study ID Numbers: 69HCL20_0250; 2021-A01792-39
• First Posted: Nov 30, 2022
• Last Update Posted: Nov 30, 2022
• Last Verified: Nov 1, 2022

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Hospices Civils de Lyon: hereditary haemorrhagic telangiectasia; endothelial cell
• Additional relevant MeSH terms: Telangiectasis; Telangiectasia, Hereditary Hemorrhagic

Study Results

No Results Posted as of Nov 30, 2022